Fibrates have been prescribed for decades as 'broad-spectrum' lipid modifying agents that can improve plasma levels of triglycerides (TGs), highdensity lipoprotein cholesterol (HDL-C), and triglyceride-rich lipoproteins (TGRL), including very low-and intermediate-density lipoproteins (VLDL and
IDL). Fibrates are variably effective in lowering LDL cholesterol (LDL-C) levels. Available fibrates include gemfibrozil, fenofibrate, bezafibrate, etiofibrate and ciprofobrate; only fenofibrate and gemfibrozil are available in Australia. Fibrates are well tolerated, and the combination of fenofibrate with statins appears to be safer than gemfibrozil, particularly with regard to adverse effects on muscle. Evidence has been provided recently for the efficacy of fenofibrate in reducing microvascular complications in diabetic patients, including progression of retinopathy, progression of microalbuminuria and nephropathy, development of sensory neuropathy, and leg amputation. Macrovascular benefits appear to be confined to those with low HDL-C and/or high TG levels, and the relationship of microvascular benefits of fenofibrate to baseline lipid levels is variable and requires further assessment. Indications for fibrate therapy may be extended in the future to include protection from both macro-and micro-vascular disease, particularly in diabetic patients and patients with residual dyslipidaemia in spite of statin therapy. We provide recommendations on the use of fibrates in clinical practice to highlight these potential indications.
Background
Fibrates are peroxisome proliferator activator receptor (PPAR)-alpha agonists, thereby activating several genes involved in lipid metabolism, the result of which includes increased fatty acid oxidation, decreased hepatic incorporation of fatty acids into VLDL and reduced VLDL production (1) (2) (3) (4) (5) (6) (7) (8) (9) . In parallel, reduced synthesis and plasma levels of apo C-3 activates lipoprotein lipase (LPL), which increases VLDL catabolism, reduces plasma concentration of large VLDL particles, and lowers plasma levels of TG. Lowering the plasma TG level is the main indication for fibrate therapy. With TG reduction, numbers of atherogenic small, dense LDL particles decrease, and numbers of less atherogenic large, less dense LDL particles increase. Potentially beneficial changes in the size distribution of LDL particles may therefore occur without change in the overall LDL cholesterol (LDL-C) concentration. Plasma concentrations of HDL and HDL-C levels also increase, partly originating from surface components of VLDL during hydolysis, and partly from increased Apo A-1 synthesis and activation of ABC-A1 cassette transporters, with activation of reverse cholesterol transport (RCT). Fibrates also decrease plasma uric acid and have anti-inflammatory properties through decreased levels of interleukin-6 (IL-6), fibrinogen, cell-adhesion molecules and C-reactive protein (CRP). These properties are consistent with anti-atherogenic effects on lipid metabolism. Fenofibrate, unlike gemfibrozil, increases serum homocysteine, creatinine and cystatin. In patients with chronic kidney disease (CKD), the dose of fenofibrate needs to be reduced, unlike that of gemfibrozil, as there is an increase in plasma levels of the drug and consequently an increased risk of side effects at usual dose (1) (2) (3) (4) (5) (6) (7) (8) (9) .
Aims
This paper reviews evidence for the benefits of fibrates in controlling dyslipidaemia, and preventing both macrovascular cardiovascular disease (CVD) and diabetic microvascular disease. It provides recommendations for the use of fibrates in clinical practice in the context of statin therapy for controlling levels of LDL-C, which remains the primary focus of therapy for preventing CVD. It supplements recent guidelines on the use of fibrates as well as reviews on TG as CVD risk factors (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) Methods Data presented herein are derived from PubMed searches, product information of fibrates, and personal clinical experience of members of the Queensland Lipid Group. Grades of recommendations ( 
Results
As a result of the panel meetings of the Queensland Lipid Group, the following recommendations and consensus grades are made on the use of fibrates in clinical practice (Table 2) . In severe HTG, plasma viscosity is also reduced by fibrate therapy, a mechanism that may also reduce the risk of acute pancreatitis. Management of patient with severe HTG aims to maintain target TG levels sufficient to prevent acute pancreatitisusually <11 mmol/L (although lower levels may be required in some patients). In moderate HTG, target TG levels are <1.5 mmol/L, which will often require fibrate therapy in combination with statins, niacin, or omega-3 fatty acids.
According to the product information for fenofibrate, patients with moderate HTG (baseline TG 3.96-5.64 mmol/) achieve reductions of 46% (p<0.05 vs placebo), 44% (p<0.05 vs placebo) and 15% (NS vs placebo) in plasma levels of TG, total cholesterol (TC) and LDL-C respectively, and levels of HDL-C increase by 20% (p<0.05 vs placebo) (21) . Patients with severe HTG (baseline TG 5.66-16.97 mmol/L) treated with fenofibrate achieve reductions of 55%, 51% and 49% in plasma levels of TG, total cholesterol (TC) and LDL-C respectively (all p<0.05 vs placebo), and levels of HDL-C increase by 23% (p<0.05 vs placebo) (21) .
High-dose n-3 fatty acids (EPA/DHA) at a dose of 2-4g daily lower TG levels with a similar efficacy to fibrates, and also augment TG lowering when added to fibrates (15) . They can be considered as either alternative or add-on therapy to fibrates for patients with moderate-severe elevation of TG levels.
Recommendation 2, (Grade A). Fibrates may be considered as secondline therapy for patients with elevated fasting TG levels less than 4.5 mmol/L, assuming adequate glycaemic control in diabetic patients and exclusion of other secondary causes of dyslipidaemia.
Mild HTG is defined as elevated TG levels between 1.7 and 4.5 mmol/L. After lifestyle modification, either fibrate or statin monotherapy may be effective in controlling TG levels in patients with mild HTG, and to achieve ideal TG levels <1.5 mmol/L (1-9). We prefer statins as first-line therapy, however, because of their predictable effects on lowering levels of LDL-C, although moderately high doses of more potent statins may be required for TG control. In general, the efficacy of statin therapy in mild HTG depends on baseline TG (more effective with higher TG levels) and dose and potency of statins with regard to LDL-C reduction (more effective in higher doses and with increasing statin potency). Nevertheless, statin therapy alone may not achieve target levels of TG and combination statin-fenofibrate therapy may be required (1) (2) (3) (4) (5) (6) (7) (8) (9) . The addition of omega-3 fatty acids (2-4g/day) may also assist in achieving target TG levels. As for patients with severe HTG, restriction of dietary refined carbohydrates, fats and alcohol is necessary, as is good glycaemic control in diabetic patients.
Fibrates reduce levels of TG-rich remnant VLDL and IDL particles, as well as postprandial lipemia (15) . These may augment the anti-atherosclerotic effects of increasing HDL-C levels (16) .
Recommendation 3.
Fibrate monotherapy may reduce LDL-C levels to a variable degree, but fibrates are not generally used for this purpose.
Fenofibrate may be considered for patients on statin therapy with elevated triglycerides. For further LDL-C reduction, alternative agents to consider include plant sterols, ezetimibe, bile resins and nicotinic acid.
Fenofibrate and baseline lipid levels
The effect of Fenofibrate on LDL-C levels depends to a large extent on the baseline lipid profile. Patients with hypercholesterolemia alone may experience 10% to 20% reduction in LDL-C levels. In patients with borderline high and high TG, LDL-C levels are often unchanged, while LDL-C levels may increase in patients with very high TG.
Fibrate monotherapy in hypercholesterolaemia (HC)
Fibrates may be effective in patients who cannot tolerate statins, and whose LDL-C levels remain above target. Fibrates are alternative second-line therapy after ezetimibe for these patients, and niacin is the alternative second-line add-on therapy as discussed below.
A study of fenofibrate monotherapy in patients with severe hypercholesterolaemia and mildly elevated TG levels (Frederickson Type IIb) resulted in reductions of 35%, 14% and 14% in plasma levels of TG, total cholesterol (TC) and LDL-C respectively (21) . Levels of HDL-C were increased by 12% (all results p<0.05 vs. placebo). Baseline lipid levels in these patients (N=242) were: TC 8.1 mmol/L, TG 2.6 mmol/L, LDL-C 5.7 mmol/L and HDL-C 1.2 mmol/L. A similar study of fenofibrate monotherapy in patients with severe hypercholesterolaemia and normal TG levels (Frederickson Type IIa) resulted in reductions of 12%, 22% and 29% in plasma levels of TG, total cholesterol (TC) and LDL-C respectively (21) .
Levels of HDL-C were increased by 12% (all results p<0.05 vs. placebo).
Baseline lipid levels in these patients (N=334) were: TC 8.0 mmol/L, TG 1.5 mmol/L, LDL-C 5.9 mmol/L and HDL-C 1.15 mmol/L (21) .
Fibrates alter the size distribution of LDL particles towards large, less dense and less atherogenic particles. Levels of IDL are also reduced, accounting for the efficacy of fibrates in familial dysbetalipoproteinaemia (apoE2 homozygosity or type III hyperlipidaemia). (16)
Fenofibrate monotherapy in combined hyperlipidaemia with mild hypertriglyceridaemia (HTG)
A 12 week study of 160mg/day fenofibrate therapy in 187 patients with mixed hyperlipidaemia whose baseline lipid levels were TC 6.7 mmol/L, TG 3.1 mmol/L, HDL-C 1.1 mmol/L and LDL-C 4.1 mmol/L resulted in 5.5% LDL-C reduction overall (30) . This response was reduced in those with LDL-C < 4.1 mmol/L, those with HDL-C <1.0 mmol/L, diabetic patients, and men vs.
women. In patients with baseline TG =<3.1 mmol/L, LDL-C was reduced by 9.9% compared with 1.1% reduction in those with baseline TG >3.1 mmol/L (the median TG was 3.1 mmol/L) (30) .
Fenofibrate monotherapy in moderate HTG
When fenofibrate was given to patients with baseline TG 4-5.6 mmol/L over an eight week period, TG levels decreased by 46% and LDL-C levels increased by 14.5%. (17) .
Fenofibrate monotherapy in severe HTG
When fenofibrate was given to patients with TG at baseline 5.6-16.9 mmol/L, TG levels decreased by 55% and LDL-C levels increased by 45%. (17) .
Fenofibrate combination therapy with statins
Fibrate therapy may be effective as second-line add-on therapy in patients whose LDL-C levels remain above target in spite of statin and/or ezetimibe therapy. The first-line choice for addition to statin therapy is ezetimibe, as it has a predictable effect in lowering LDL-C (~20%), and is well tolerated. (22) Ezetimibe therapy results in smaller effects on plasma lipid levels other than LDL-C.
In the SAFARI trial, simvastatin 20 mg/day plus fenofibrate 160 mg/day was compared with simvastatin alone in 619 patients with combined hyperlipidaemia over a 12 week period ( Table 5 ). (23) Compared with statin monotherapy, statin-fibrate therapy increased HDL-C and apoA-1 levels and decreased levels of TG, LDL-C, non-HDL-C and apoB (Table 4 ). There were no cases of clinical myopathy or rhabdomyolysis (23) . With fenofibrate therapy, the proportion of large LDL particles increased from 9.2% at baseline to 28.6%, and the proportion of small dense LDL particles decreased from 72.2% at baseline to 32.1% (23) . (30) . The ezetimibe product information, however, warns that combination therapy with fibrates can result in 1.5 fold increase in ezetimibe plasma levels, but no clinical adverse events were experienced in the above study (31). A subsequent study showed further benefit from fenofibrate combined with simvastatin/ezetimibe (32) .
In other trials, fenofibrate-statin therapy had limited additional effects on plasma lipid levels compared with statin monotherapy (24) . 
The FIELD and ACCORD studies
The large FIELD and ACCORD studies of fenofibrate in diabetic patients did not show significant reductions in LDL-C levels compared with placebo.
FIELD was a study of 9,795 asymptomatic diabetic patients randomised for 5 years to placebo vs fenofibrate therapy, with additional therapy at the discretion of the treating physician (28) . After 4 months there was a 12% (0.4mmol/L) reduction in LDL-C levels in the fenofibrate vs placebo group, and after 3 years there was no difference. The data was difficult to interpret because of a significant proportion of drop-ins with statin therapy, which was greater in the placebo group than the fenofibrate group. The ACCORD study treated 5,518 diabetic patients (one-third of whom had CAD) for 4.7 years with either fenofibrate or placebo, on a background of open-label simvastatin therapy (29) . Levels of LDL-C did not change significantly in the fenofibratetreated group, and were not significantly different from the placebo-treated group (29) . The data from these large trials suggest there may be less reduction of LDL-C with fibrates in diabetic patients compared with nondiabetic patients, but other causes may also be involved such as differences in baseline levels and whether or not statins are used.
Niacin as an alternative to fenofibrate for add-on therapy with statins
An alternative first-line add-on therapy with statins is niacin. The advantage of niacin is that it decreases LDL-C more than fibrates, has a greater effect on raising HDL-C, and also lowers Lp (a) levels (25) . The problem is that niacin is so poorly tolerated. Probably less than 10% of patients can tolerate 3000mg per day for an extended period.
The lack of clinical outcomes data, such as results of the AIM-HIGH study, however, has to be considered (26). AIM-HIGH was a five-year study of almost 3500 patients with low HDL-C, designed to examine whether raising HDL using extended-release niacin would be beneficial. The trial was stopped extended-release niacin offered no benefits beyond statin therapy alone in reducing cardiovascular-related complications. There was no evidence that this would change by continuing the trial. Use of niacin with statins now depends on results of HPS2-THRIVE, a large clinical outcomes trial in which extended-release niacin in combination with simvastatin and laropiprant (an inhibitor of the niacin receptor responsible for skin flushing) is compared with placebo and simvastatin therapy (27) .
Other combination therapy with statins
Other therapies which effectively lower LDL-C as add-on to statins include plant sterols, 2-4 g/day, and bile sequestrants (4-20g/day).
Recommendation 4, (Grade A). Fenofibrate is preferred to gemfibrozil for combination therapy with statins in order to reduce the likelihood of adverse effects on skeletal muscle.
Fibrate monotherapy is not frequently associated with myalgia, although the incidence may be increased with concomitant statin therapy, especially gemfibrozil (33) (34) (35) (36) (37) (38) (39) . Gemfibrozil inhibits glucuronyl transferase, one of the enzymes involved in the liver's excretion pathways for statins. The enzyme catalyses attachment of a glucuronyl ring to statin molecules and facilitates their hepatic uptake and excretion into bile. When administered with gemfibrozil, blood levels of statins may be considerably raised because of increased Cmax, time/concentration area under the curve (AUC), and t½ of the statin or its active metabolites (33) . The AUC with gemfibrozil plus statin is two-to fourfold greater than with a statin alone. The higher the statin blood level, the greater the risk of myopathy and rhabdomyolysis. In contrast to gemfibrozil, fenofibrate does not inhibit hepatic glucuronyl transferase, and does not result in significant elevation in plasma levels of statins nor have any significant effect on the incidence of muscular side effects (37, 38) . It was concluded that fibrates improve lipid profiles and are associated with decreased nonfatal MI, but have no substantial effect on all-cause mortality. It was suggested that clinical use of fibrates include treatment for patients with statin resistance or isolated hypertriglyceridemia (HTG), or as an adjunct to other lipid-lowering therapies (5) . Reduction in CAD risk would appear to be greater if fibrates were reserved for patients with atherogenic dyslipidaemia (high TG and low HDL-C) (5) . Similar conclusions were reached in another meta-analysis (40) . Improvement in DMVD with fibrate therapy was first reported in the FIELD study, which showed lower rates of laser therapy for diabetic proliferative retinopathy (DPR) (42) . Similar but even more pronounced benefits for diabetic retinopathy (DR) were observed on the ACCORD-EYE substudy, which differed in several respects from the FIELD study in design and reporting characteristics (48, 49) . Using a standard ophthalmological scale, progression of DR in ACCORD-Eye required ≥3 step progression in both eyes, while 1 or 2 step progression in the worst eye sufficed in FIELD. Preexisting DR occurred in 50% and 20% of patients, and the duration of type 2 diabetes was 10 years and 5 years in ACCORD-Eye and FIELD respectively.
In ACCORD-EYE there was a 40% lower rate of laser therapy in the fenofibrate-simvastatin treatment group (6.5% over 4 years) compared with the placebo-simvastatin group (10.2%, adjusted OR 0.6, 95% CI 0.42-0.87, p=0.006). In contrast to this significant improvement, effects of statin therapy on DR progression have been inconsistent (48, 49) . As suggested by the results of the FIELD study, much of the benefit for DR in ACCORD-EYE is likely to be due to fenofibrate therapy rather than to combination statin-fibrate therapy.
In the FIELD study non-traumatic amputations for DMVD were also reduced in the fenofibrate group compared with the placebo group, in spite of increased statin drop-ins in the placebo group (43) (44) (45) (46) Renal microvascular disease is detected and quantified by measurement of urinary albumin concentrations (50) . In non-diabetic patients, significant proteinuria is present when the urinary albumin: creatinine ratio (ACR) is 30 mg/mmol or more (equivalent to a protein excretion of 0.5g/24h or more) (50) .
In diabetic patients, microalbuminuria is clinically significant if ACR >2.5 mg/mmol in men and >3.5 mg/mmol in women (50) . In the FIELD study, reduced estimated GFR (eGFR) and albuminuria were independent risk factors for cardiovascular events and mortality rates. Albuminuria increased CVD risk, with microalbuminuria and macroalbuminuria increasing total CVD Fenofibrate reduced albuminuria and slowed estimated GFR loss over 5 years, despite initially and reversibly increasing plasma creatinine. During fenofibrate run-in, plasma creatinine increased by 10.0 μmol/l (p < 0.001), but quickly reversed on placebo assignment. It remained higher on fenofibrate than on placebo, but the chronic rise was slower (1.62 vs 1.89 μmol/l annually, p = 0.01), with less estimated GFR loss (1.19 vs 2.03 ml min (-1)
1.73 m (-2) annually, p < 0.001).
After washout, estimated GFR had fallen less from baseline on fenofibrate (1.9 ml min (-1) 1.73 m (-2), p = 0.065) than on placebo (6.9 ml min (-1) 1. [95% CI 9-18]; p < 0.001), with 14% less progression and 18% more albuminuria regression (p < 0.001) than in participants on placebo. End-stage renal event frequency was similar (n = 21 vs 26, p = 0.48).
The FIELD study therefore suggested fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients. (28) Reduced progression of albuminuria was also observed with fenofibrate therapy in the DAIS trial (52) . In the ACCORD trial, post-randomisation MiA occurred in 38.2% and 41.6% of patients treated with fenofibrate and placebo respectively (p=0.01) (51). Post-randomisation MaA occurred in 10.5% and 12.3% of patients treated with fenofibrate and placebo respectively (p=0.03).
The possible mechanisms by which microavascular protection may occur with fenofibrate therapy include improved endothelial-dependent vascular reactivity, anti-inflammatory effects with reduction in pro-inflammatory markers (interleukin-6, interleukin 1-beta, tumour necrosis factor alpha), reduced plasma viscosity, improved insulin sensitivity, protection from ischaemia, reduction in apoptosis, increased nitric oxide synthesis, and neuroprotective effects (43, 44) .
Other issues
Uniform agreement of the panel was not always reached on a number of issues, reflecting the varied opinions of experts and consensus panels elsewhere and the need for further research to provide more robust data from which to draw conclusions. One such area relates to cut-off levels for HDL-C and TG for which fibrate therapy is indicated to control residual risk (the risk of CVD remaining in spite of statin therapy). Some authorities suggest appropriate TG levels are >2.2 mmol/L, others >2.0 mmol/L as in the CSANZ /Heart Foundation of Australia Lipid position statement (58) . Cut-points are, however, arbitrary and driven by retrospective analyses of subgroups in fibrate trials. No prospective trial has yet been performed with these cut-points as inclusion criteria, although such a trial for fenofibrate was recently recommended by the FDA to confirm subgroup analysis of the ACCORD-Lipid trial showing benefit in dyslipidaemic diabetic patients (29) . We have given grade B to recommendation 5 for these reasons.
Cut-offs for HDL-C are also arbitrary and also reflect subgroup analyses of fibrate trials. Fibrates increase HDL-C levels, especially in those with low baseline levels. This was shown in a large study of 7,098 patients with dyslipidaemia, treated with placebo or micronised fenofibrate 200 mg daily (bioequivalent to fenofibrate 160 mg tablets) for 24 weeks (47) . The increase in HDL-C levels was inversely related to baseline levels, being +22.7% overall, + 90.2% (lowest quintile, baseline HDL-C levels < 0.65 mmol/L, mean increasing from 0.54 to 1.00 mmol/L), +58.3% (second lowest quintile, baseline HDL-C < 0.77 mmol/L, mean increasing from 0.66 to 1.02 mmol/L), +44.3% (middle quintile, baseline HDL-C <0.9 mmol/L, mean increasing from 0.76 to 1.07 mmol/), +36.1% (second highest quintile, baseline HDL-C <1.03 mmol/L, mean increasing from 0.84 to 1.02 mmol/L), + 31.6% (highest quintile, baseline HDL-C levels< 1.16 mmol/L, mean increasing from 0.89 to 1.16 mmol/L). All HDL-C levels in the fenofibrate group were higher than placebo (p < 0.0001).
The effect of fenofibrate on HDL-C was also greatest among high-risk patients with low levels of HDL-C (53). These changes were higher than those reported in the clinical outcomes trials with fibrates, and most studies show increases in HDL-C between 5-15%. Elevation of HDL-C appears to be blunted in diabetic patients, in whom the functionality of HDL may also be impaired. Low levels of HDL-C may therefore be targeted in patients on statin therapy in order to improve residual risk, in much the same way that elevated TG levels are also targeted. Because disturbances in HDL-C and TG occur together, it is debatable as to whether there is benefit to be gained by targeting one lipoprotein vs. the other. The answer to this question will be provided by results of trials with drugs that specifically raise HDL-C and have little impact on other lipoprotein classes. The cholesterol ester transfer protein (CETP)
inhibitors may closest to such as class, although they also lower LDL-C and TG levels. Studies with recombinant HDL have suggested that targeting HDL-C alone in patients with acute coronary syndrome (not necessarily with low HDL-C levels) is likely to be beneficial, as rapid regression of coronary atherosclerosis has been observed (55) . This is currently an area of intensive research.
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In the meantime, fibrates and niacin are reasonably effective in raising HDL-C levels. Omega-3 fatty acids may result in similar improvement in patients with HTG (56) . In general, the lower the HDL-C level, the greater in the percentage increase, although achieving target HDL-C levels (> 1.0 mmol/L) in patients with baseline levels <0.5 mmol/L remains problematic. The effectiveness of lipid modifying drugs in raising HDL-C is shown in Table 5 . There is considerable variation in reported effects of fibrates and other drugs on raising HDL-C in clinical trials and in individual patients. This is not unexpected, given the complexity of HDL-C metabolism and its interaction with other plasma lipoproteins.
Conclusions
The The relationship of baseline lipids to microvascular benefits of fenofibrate in diabetic subjects is currently under intense investigation as are the mechanisms for benefit. It seems likely that multiple biochemical pathways are involved, reflecting the complex gene effects of PPAR-alpha agonism.
Microvascular benefits of fibrates other than fenofibrate may also occur, as these drugs share a common mechanism of action. Publications on these topics from the FIELD and ACCORD study investigators are anticipated in the near future. These, as SW and DC have no potential conflicts to declare.
